China nod to two Sanofi drugs for rare and complex conditions
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
Experts caution that realizing AI’s potential requires careful management and risk mitigation
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Subscribe To Our Newsletter & Stay Updated